Additionally, a biomimetic delivery nanoplatform has been designed for HCC treatment by self‐assembling a PD‐L1‐targeted CRISPR/Cas9 system with ursolic acid (UA). This evidence concerns the gene CD274 and hepatocellular carcinoma.